T-VEC

DRUG3 trials

Sponsors

H. Lee Moffitt Cancer Center and Research Institute, The Netherlands Cancer Institute, University of California, Davis

Conditions

Angiosarcoma of SkinMelanomaMelanoma Stage IIIMelanoma Stage IV

Phase 2

Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma

TerminatedNCT03921073

H. Lee Moffitt Cancer Center and Research InstituteAngiosarcoma of Skin

Start: 2019-08-20End: 2021-09-28Updated: 2022-11-01

Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease

CompletedNCT04330430

The Netherlands Cancer InstituteMelanoma Stage III, Melanoma Stage IV

Start: 2020-09-08End: 2025-01-29Updated: 2025-03-12

Neoadjuvant T-VEC in High Risk Early Melanoma

SuspendedNCT04427306

University of California, DavisMelanoma

Start: 2020-05-21End: 2024-05-21Updated: 2023-09-15

Related Papers

Recent Advancements in Cell-Based Therapies in Melanoma.

2024-09-124 citations

622 Immune phenotype and iFRET functional analysis are biomarkers of response to neoadjuvant intralesional therapy for high risk stage II melanoma

Regular and Young Investigator Award Abstracts2023-10-311 citations

Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial.

Journal of Clinical Oncology2023-06-0110 citations

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial

BMC Cancer2022-08-0434 citations

Neo-adjuvant T-VEC plus nivolumab combination therapy for resectable early-stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: The NIVEC trial.

Journal of Clinical Oncology2022-06-01